First bulk wholesale deal for MMJ Phytotech

Published at Nov 19, 2015, in Biotech

MMJ Phytotech (ASX:MMJ) has bagged its first wholesale sale of its Satipharm CBD pill, a sale which could open doors for the pharmaceutical player.

It told the market today that it had secured a $225,000 sale to UK supplement distributor Prima Sport, with the pill to be sold through a dedicated portal on the Prima Sport website.

MMJ said it expects the order to be sold to customers within the first half of next year and it was in discussions with other European companies about doing a similar deal.

“This partnership with Prima Sport, a leading supplement distributor, provides MMJ with access to a larger market within the United Kingdom and has the potential to raise further awareness of our CBD capsules,” MMJ managing director Andreas Gedeon said.

“This agreement also opens up further opportunities with Prima Sport and other distributors to wholesale further products and accelerate our wholesale strategy.”

MMJ first bagged a sale of its CBD pill back at the end of August, but this was from its own website rather than a wholesale bulk deal.

MMJ has also recently signalled that it intends to pursue a market entry in Australia on the back of regulatory wins in several states.

The pharmaceutical company raised $2 million to fund the market entry, but further bulk wholesale deals could provide a step-change in revenue for the company and fund further entries or acquisitions.

About MMJ Phytotech

The ‘farm to pharma’ company grows cannabis plants in Canada to extract the vital medicinal ingredients from the plant.

It then sends them off to Switzerland, where its subsidiary Satipharm develops products such as the CBD pill from them.

It also has its eyes on being a pharmaceutical developer and distributor of cannabinoid “Active Pharmaceutical Ingredients” (APIs), which are highly valuable and for cannabinoid (CBD), can be traded at prices upwards of $350,000 per kilogram.

It also has a R&D offshoot in Israel which works on research and product development.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn